Europe made organ matching cross borders
A donated organ is one of medicine's rarest gifts and one of its most time-sensitive responsibilities. Once a deceased donor becomes available, a kidney, liver, heart, lung, pancreas or intestine must be characterised, matched, offered, transported and transplanted through a chain that can span hospitals and borders. Eight European countries decided that this search should not stop at the edge of a national waiting list. They built Eurotransplant, a shared allocation network operating every hour of every day.
That is a European achievement worth stating plainly. Austria, Belgium, Croatia, Germany, Hungary, Luxembourg, the Netherlands and Slovenia pool a region of about 139 million people. Seventy-nine transplant centres register the relevant characteristics of patients in one centrally administered system, donor information enters the same network, and trained duty officers turn agreed medical and ethical rules into urgent offers. Europe made solidarity operational at the moment when minutes matter.
From a 1967 experiment to shared infrastructure
The idea began in Leiden in 1967. Immunologist Jon van Rood had shown how human leukocyte antigens, or HLA, influence kidney-transplant compatibility and survival. A larger patient pool increased the chance of finding a suitable tissue match, so twelve centres in three countries voluntarily shared recipient and donor information. What began as a scientific experiment became lasting infrastructure because the clinical logic and the European logic pointed in the same direction: a compatible patient may live across the border.
Eurotransplant later expanded from kidneys to livers, hearts, pancreas, lungs and intestines. Slovenia joined in 1999, Croatia in 2007 and Hungary in 2013, creating today's eight-country network. The organisation also changed its governance as it grew. Its Assembly, management and supervisory boards, councils and advisory committees give national authorities, transplant societies, centres, laboratory experts and ethics specialists formal routes into policy and allocation development.
The 2025 network in numbers
The 2025 figures show the operating scale. Eurotransplant reports that 2,221 deceased donors supplied 7,366 organs successfully allocated to waiting patients, up from 7,150 organs in 2024. The year ended with 13,686 people on the active waiting list. These counting methods distinguish organs, donors and recipients, so they should not be collapsed into one transplant number. They do show a shared service repeatedly coordinating life-changing decisions across a population larger than most countries.
Cross-border exchange is not decorative. In 2025, 20.5% of allocated organs moved between Eurotransplant member countries. That means roughly one organ in five found its recipient through a national border rather than despite it. The proportion can change from year to year, and not every organ should travel: local suitability, urgency, transport time and national balance matter. The central accomplishment is a system able to look wider when a wider search produces the medically and ethically stronger match.
Why a larger patient pool saves opportunities
A larger pool matters most where a match is difficult. Children, highly immunised patients, people with rare blood or tissue characteristics and patients in acute organ failure can have especially narrow opportunities. Shared allocation increases the chance that an unusual donor-recipient combination can be recognised in time. It also lets an organ that has no suitable recipient in the donor country reach a patient elsewhere instead of remaining unused merely because the national list is smaller or differently composed.
Who does what in the allocation chain
The process begins locally. Hospitals identify a potential donor under national law and clinical protocols; authorised professionals determine death, consent and organ suitability; and donation organisations coordinate procurement. Eurotransplant does not recruit donors, decide whether a family must consent, perform the operation or own the organ. Its responsibility is the allocation service: receive verified characteristics, generate a recipient-oriented match list, make and document offers, and maintain the shared information system.
The matching algorithm is not a marketplace and no patient buys a place. Eurotransplant describes four broad considerations: expected outcome, medical urgency, waiting time and a reasonable national organ balance. Organ-specific rules add far more detail. A duty officer screens the computer-generated match list and offers the organ to the transplant centre for the highest-ranked named recipient, often alerting the next centre provisionally so time is not lost. The treating team still decides whether the offer is clinically acceptable for that patient.
Transparent rules, data and human judgment
Transparency is part of the infrastructure. The public Eurotransplant Manual sets out definitions, international exchange policies, waiting-list and high-urgency rules, donor procedures and the kidney, liver, thoracic, pancreas and intestine allocation systems. Advisory committees analyse data and propose revisions; national competent authorities review recommendations against national law. The same answer should produce the same match list, and every operational step should be accountable, even though individual medical data must remain protected.
Technology supports rather than replaces judgment. Tissue-typing laboratories contribute HLA information; the central system compares donor and patient characteristics; and a virtual crossmatch introduced in 2023 for specified kidney and pancreas programmes uses detailed immunological data to assess incompatibilities before a physical laboratory crossmatch. Better data can save precious time and avoid unsuitable offers, but clinicians remain responsible for donor assessment, recipient condition and the final transplant decision.
European safety law without one European hospital
The network works because Europe also built common safety law around it. Directive 2010/53/EU establishes minimum quality and safety requirements from donation and testing through characterisation, procurement, preservation, transport and transplantation. National competent authorities supervise the chain, while Council of Europe experts through the EDQM develop detailed professional guidance and human-rights standards. Eurotransplant is not an EU agency; it is a European foundation operating inside this layered public framework.
That institutional precision matters. Eurotransplant covers eight countries, not the whole EU or continent. Other European systems include Scandiatransplant and national or bilateral arrangements. Donation consent, waiting-list access, transplantation capacity and funding remain national. A person cannot register directly with Eurotransplant or demand an organ from another country; the treating transplant centre evaluates and lists the patient under the applicable programme and law.
Organ exchange is also different from ordinary planned healthcare abroad. The S2 planned-treatment guide explains authorisation and reimbursement for a patient travelling for specified care. Eurotransplant coordinates a scarce donated organ toward an allocated recipient through transplant programmes. It is not a booking route, a general second-opinion network or a guarantee that surgery will occur in another country. The European Reference Networks similarly move expertise, but they do not allocate organs.
Scarcity remains the central unfinished task
The ethical weight is enormous because supply cannot meet need. At the end of 2025, 13,686 people remained actively listed, including 10,359 awaiting a kidney when patients waiting for multiple organs are counted under each needed organ. Waiting-list status can change with health, and removal data must be interpreted carefully, but the overall fact is unambiguous: successful allocation does not erase the shortage. Donation, prevention, living-donor programmes, equitable listing and responsible use of every viable organ remain urgent public work.
Countries also bring different donation rates, hospital capacity and consent systems into the pool. A reasonable national balance is therefore part of allocation, while highly urgent and difficult-to-match patients may need international priority. Solidarity cannot mean quietly relying on neighbours to supply organs while underinvesting at home. Each member needs trained coordinators, intensive-care identification, trustworthy registries, transplant teams, public accountability and respectful family communication.
Transport is a physical limit no algorithm can abolish. Different organs tolerate different periods outside the body; weather, aircraft, road links, operating theatres and laboratory timing can decide whether an allocation is usable. Eurotransplant makes the offer and coordinates information, while national organisations and centres arrange procurement and transport. New preservation and perfusion technologies can extend assessment and use, but their oversight and access remain uneven and must not be marketed as an end to scarcity.
Trust, dignity and accountability
Trust is the system's irreplaceable input. Donation must rest on lawful consent, dignity, privacy and a strict prohibition on financial gain from human organs. Allocation rules must remain medically justified, reproducible and open to review. Patients and families need honest information about uncertainty rather than a promise that one ranking number tells the whole story. European cooperation earns legitimacy when it treats the donor, recipient and unsuccessful waiting patient as people, not units moving through logistics software.
Solidarity as a working capability
Europeans can be proud that a discovery about tissue compatibility became a permanent institution of solidarity. For nearly six decades, countries have shared the hardest parts: data, scarce organs, ethical rules, scientific learning and the obligation to help the patient who is the best match even when that patient lives elsewhere. In 2025, more than 1,500 allocated organs crossed a member-country border. Behind each transfer was a donor, a grieving family, a waiting patient and a European system prepared to connect them.
Eurotransplant offers a precise federal lesson. National health systems did not disappear, and no central body took over every hospital decision. Countries pooled the function whose value grows most clearly with scale: finding the right recipient quickly and fairly across a larger population. The next work is substantial—more donation, better access, stronger data, safer preservation, enough staff and continuous scrutiny—but Europe has already proved the essential principle. When life depends on a match, cooperation is not sentiment. It is capability.